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Abstract. In 2009, vinflunine was introduced as a second‑line 
treatment to be used after the failure of platinum therapy in 
patients with metastatic urothelial carcinoma (mUC). The 
present study investigated the administered vinflunine to 
patients with mUC in standard clinical practice with the aim 
of evaluating treatment patterns, response, survival param-
eters and side‑effects. Data were collected retrospectively 
from the first 100 mUC patients treated with vinflunine 
at three Nordic cancer centers associated with the Nordic 
Urothelial Cancer Oncology Group. The overall response 
rate was 23% and complete response was observed in one 
patient. The median progression‑free survival (mPFS) and 
median overall survival (mOS) were 2.8 (range, 0.5‑34.3) and 
6.3 (range, 0.3‑39.7) months, respectively. An Eastern Coop-
erative Oncology Group performance status (ECOG PS) of 2 
was present in 20% of the patients, and those patients exhibited 
significantly shorter mOS (4.1 vs. 7.0 months, P=0.001) and 
a significantly higher degree of grade 3/4 toxicity (P=0.026) 
compared with ECOG PS 0‑1 patients. Furthermore, patients 
without visceral metastases had significantly longer mOS 
than patients with visceral metastases (10.6 vs. 6.0 months, 
P=0.008). The median number of cycles of vinflunine was 
3 (range, 1‑28). The current data confirms that vinflunine is 
an active agent for second‑line treatment in an unselected 
clinical cohort of patients with mUC. ECOG PS and presence 
of visceral metastases were significant prognostic parameters. 
In particular, patients with ECOG PS 2 receiving vinflunine 
had a shorter mOS and a higher frequency of severe toxicity, 
and, thus, should be treated with caution. Furthermore, the 
present study observed large inter‑individual differences in 
radiological response and OS, indicating the need for further 
development of improved patient selection tools to optimize 
vinflunine treatment in platinum‑refractory mUC patients.
Introduction
Metastatic urothelial carcinoma (mUC) is a chemo-
therapy‑sensitive disease, and platinum‑based chemotherapy 
is the standard primary treatment for patients with this form 
of cancer. Although the response rate to such treatment is 
>50% (1), the vast majority of patients eventually develop 
platinum resistance and progressive disease, and are, thus, 
candidates for second‑line treatment. During the recent 
decades, numerous therapeutic agents and combination regi-
mens have been evaluated in the second‑line setting of mUC 
treatment, including conventional cytotoxic agents (2‑5) and 
targeted compounds (6‑11). In general, these trials have been 
small and had negative outcomes, and very few treatments 
have been investigated in randomized trials.
In 2009, the European Medicines Agency approved 
vinflunine for second‑line treatment of mUC based on 
the results of two phase II trials and one core randomized 
phase III trial (12). The phase III trial revealed that, compared 
with using best supportive care alone, the administration of 
vinflunine provided a small but significant median overall 
survival (mOS) benefit of 2.3 months in the eligible population 
(P=0.036). Despite the low response rate, disease control was 
achieved in >40% of the patients with unaltered quality of life, 
and an acceptable and manageable toxicity profile (12). Based 
on these observations, vinflunine was the first compound 
to be approved for second‑line treatment of mUC. Recently 
published long‑term follow‑up data confirmed the previously 
reported OS benefit (13) and vinflunine is the recommended 
second‑line treatment in the European Association of Urology 
guidelines (14). This treatment strategy has been implemented 
in Denmark and Sweden.
The introduction of vinflunine should be considered a 
small but important step toward improved OS in patients 
with mUC (15). However, the treatment of platinum‑refrac-
tory patients remains a clinical challenge, and further 
improvement in the outcome of such patients will require the 
development of novel and more efficient treatment strategies. 
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Two potential approaches have emerged in this context: 
i) Using vinflunine as the backbone in a combined treat-
ment strategy; and ii) identifying novel and more effective 
compounds. An example of the former strategy was recently 
reported by a German group that performed a phase I/II trial 
to evaluate the safety, tolerability, and efficacy of combining 
vinflunine with the antiangiogenic, multi‑targeted receptor 
tyrosine kinase inhibitor, pazopanib (16). However, this 
combination was poorly tolerated, and the study was inter-
rupted at dose level 1 due to toxicity. A similar phase I 
trial is currently being performed by the Nordic Urothelial 
Cancer Oncology Group (NUCOG) to analyze another 
kinase inhibitor, sorafenib, in combination with vinflunine 
(ClinicalTrials.gov Identifier: NCT01844947). Several other 
promising new drugs and approaches are also being inves-
tigated in phase I/II studies, including the following (17,18): 
Cytotoxic compounds (cabazitaxel, nab‑paclitaxel); targeted 
drugs inhibiting mechanistic target of rapamycin (temsi-
rolimus), phosphoinositide 3‑kinase (buparlisib), human 
epidermal growth factor receptor 1/2 (lapatinib) and fibroblast 
growth factor receptor 3 (dovitinib); inhibitors of angiopoi-
etin 1/2 (trebananib) and proteasomes (bortezomib); vaccine 
approaches (cdx‑1307); and immunotherapy targeting the 
programmed cell death 1 signaling pathway.
Patients with platinum‑refractory disease are heteroge-
neous in terms of performance status, comorbidities, renal 
function and the pattern of metastatic tumor burden, and, thus, 
they may benefit differently from second‑line treatment. Bell-
munt et al (19) demonstrated that the following three clinical 
parameters are independent prognostic factors in patients with 
platinum‑refractory disease receiving second‑line treatment 
with vinflunine: Low hemoglobin (Hb) level (<10 g/dl), an 
Eastern Cooperative Oncology Group performance status 
(ECOG PS) of ≥1 and the presence of liver metastases. Based 
on these prognostic factors, the patients may be categorized 
into four groups with significant differences in mOS. Notably, 
the mOS was 14.2 months in patients with none of the adverse 
prognostic factors but was only 1.7 months in those with all three 
risk factors (P<0.001) (19). A recent retrospective analysis of 
seven prospective phase II trials demonstrated that short time 
from previous first‑line chemotherapy is another risk factor 
significantly associated with poor prognosis. This finding may 
facilitate prognostic risk classification for second‑line treat-
ment (20), and has also led to the suggestion that nomograms 
can be used to predict the effect of second‑line therapy (21). 
In further attempts to identify the patients that will most 
benefit from vinflunine treatment (22), it was demonstrated 
that a >10% reduction in the sum of the longest axis diameter 
of the target lesions was a better early predictor of survival 
compared with response evaluation criteria in solid tumors 
(RECIST). Furthermore, it has been demonstrated that the 
type of platinum treatment administered prior to vinflunine 
(i.e., cisplatin or carboplatin) has no impact on the subsequent 
benefit of vinflunine (20,23).
The overall aim of the present study was to evaluate the 
outcome and toxicity of second‑line treatment with vinfl-
unine administered to patients with mUC in standard clinical 
practice, and to identify the patients that most benefit from 
such treatment. The present study retrospectively analyzed 
collected demographic data, treatment patterns, survival 
parameters and side‑effects for the first 100 patients treated 
with vinflunine at three Nordic cancer centers. The data were 
also assessed to determine whether they could be used to 
validate the three previously suggested prognostic factors for 
mUC: ECOG PS ≥1, <10 g/dl Hb and the presence of liver or 
visceral metastases (19,24).
Patients and methods
Patients and data collection. The cohort comprised the first 
100 mUC patients to be treated with vinflunine between 
February 2010 and July 2013 at three Nordic centers: 
Karolinska University Hospital (Stockholm, Sweden), 
Rigshospitalet (Copenhagen, Denmark) and Odense Univer-
sity Hospital (Odense, Denmark). All three of these centers 
participate in the NUCOG collaboration. The start of data 
collection coincided with the time points of the national 
decisions to initiate use of vinflunine as standard second‑line 
treatment in the two countries (February 2010 in Denmark and 
July 2010 in Sweden).
Data were retrospectively collected from patient charts 
and covered the following: Patient and disease characteristics, 
prior treatment, including type of platinum‑containing chemo-
therapy, vinflunine treatment, toxicity, response, and survival 
parameters. For further analyses, two subgroups were defined 
according to ECOG PS status: ECOG PS 0‑1 and ECOG PS 2. 
Patients that had not received platinum‑containing chemo-
therapy prior to vinflunine were excluded from the analyses of 
response and survival.
The trial was approved by the Research Ethics Committee 
in Stockholm, Sweden (approval no. Dnr 2013/664‑31/3). 
Written informed consent from the patients was waived by the 
committee.
Definition of treatment response. Response rates were calcu-
lated based on standard radiological evaluations (i.e., computed 
or magnetic resonance tomography), conducted according to 
routine practice at each center. Responses were evaluated by 
the local radiologist at each center according to RECIST 1.1 
criteria (25). The disease control rate (%) was defined as 
the sum of patients with stable disease, partial response and 
complete response.
Definitions of PFS and OS. Progression‑free survival (PFS) 
was defined as the period from the date of the first vinflunine 
treatment to the date of radiological progression. Patients with 
no radiological evaluation (n=18) were excluded from the PFS 
analyses. OS was defined as the period from the date of the 
first vinflunine treatment to the date of mortality or the date of 
the most recent follow‑up (26).
Toxicity. Toxicity assessment was graded according to the 
National Cancer Institute's Common Terminology Criteria 
for Adverse Events (NCI‑CTCAE; version 4.0) (27). Grade 3 
and 4 toxicities for all common vinflunine‑associated 
hematological and non‑hematological adverse events were 
recorded.
Statistical analysis. Univariate and multivariate analyses of 
time to event data (PFS and OS) were performed using the 
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log‑rank (Mantel‑Cox) model. Survival curves were estimated 
using the Kaplan‑Meier method. Differences in nominal data 
were assessed by the Pearson χ2 test. P<0.05 was used to indi-
cate a statistically significant difference. Data were analyzed 
using SPSS statistics software for Windows (version 22.0; IBM 
SPSS, Armonk, NY, USA).
Results
Patient characteristics. Characteristics of the total patient 
cohort are listed in Table I. The cohort included 72% men and 
the median age was 68 years (range, 45‑81 years). The majority 
of the primary tumors (84%) were located in the bladder and 
Table I. Characteristics of patients with metastatic uroethelial cancer.
 All patients ECOG PS 0‑1 ECOG PS 2
Characteristic (n=100) (n=80) (n=20)
Gender
  Male 72 (72) 60 (75) 12 (60)
  Female 28 (28)  20 (25)   8 (40)
Age, years
  Median 68 68 68
  Range 45‑80 45‑81 46‑79
Primary tumor location 
  Bladder 84 (84) 66 (85) 15 (75)
  Upper urinary tract 16 (16) 11 (14)   5 (15)
  Urethra 2 (2) 1 (1) 0 (0)
Metastatic site
  Lymph nodes 66 (66) 55 (69) 11 (55)
  Lung 48 (48) 35 (44) 13 (65)
  Liver 25 (25) 20 (25)   5 (25)
  Bone 18 (18) 14 (18)   4 (20)
  Other 17 (17)  14 (18)   3 (15)
Visceral metastases  
  No 24 (24) 22 (28)   3 (15)
  Yes 76 (76) 58 (72) 17 (85)
ECOG PS
  0 30 (30) 30 (38) ‑
  1 50 (50) 50 (62) ‑
  2 20 (20) ‑   20 (100)
GFR, ml/min
  Median 58 59 58
  Range 21‑124 27‑124 21‑100
<10 g/dl Hb 39 (39) 25 (34) 11 (50)
Primary curative treatment
  Primary surgery 40 (77) 33 (77)   7 (78)
  Primary radiotherapy 12 (23) 10 (23)   2 (22)
  Perioperative chemotherapy  14 (27) 10 (23)   4 (44)
  Total 52 (52) 43 (54)   9 (45)
Prior chemotherapy
  Cisplatin/gemcitabine 76 (76) 63 (82) 12 (67)
  Carboplatin/gemcitabine 17 (17) 14 (18)   4 (22)
  Other 2 (2) 0 (0)   2 (11)
Chemotherapy cycles prior to vinflunine, n
  Median 6 6 6
  Range 0‑20 0‑20 0‑16
All data, excluding age, GFR and cycles prior to vinflunine, is presented as n (%). ECOG PS, Eastern Cooperative Oncology Group perfor-
mance status; GFR, glomerular filtration rate; Hb, hemoglobin.
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approximately half (52%) of the patients had undergone primary 
curative treatment with surgery (cystectomy or nephroureterec-
tomy) or radiotherapy. Furthermore, 27% of those administered 
with primary curative treatment had received perioperative 
chemotherapy with three cycles of gemcitabine and cisplatin.
The vast majority (95%) of the patients had received first‑line 
platinum‑containing chemotherapy (cisplatin or carboplatin) 
prior to vinflunine. Five patients underwent no chemotherapy 
prior to vinflunine and were excluded from further analyses 
of response and survival. A median of 6 cycles of first‑line 
chemotherapy (range, 0‑20 cycles) was administered prior the 
commencement of vinflunine treatment (Table I), and 62% 
of the patients received ≥6 cycles. Grounds for discontinuing 
first‑line treatment were as follows: Disease progression (88%), 
toxicity (9%) and other reasons (3%; data not shown).
At the onset of vinflunine treatment, 4% of patients had 
local recurrence in the bladder and 96% had metastatic disease. 
The most common locations of metastases were lymph nodes 
(66%), lungs (48%) and the liver (25%). No evidence of visceral 
metastases was observed in 24% of the patients. The ECOG PS 
was 0 in 30%, 1 in 50% and 2 in 20% of the patients (Table I).
Vinflunine treatment. Vinflunine was administered as first‑line 
treatment in 5% of patients, as second‑line treatment in 94% 
and as third‑line treatment in 1% (Table II). The median 
number of cycles of vinflunine treatment was 3 (range, 1‑28) 
and the starting dose was 280 mg/m2 in 46% of the patients. 
Dose reduction was performed in 19% and treatment delay 
occurred in 18%. In addition, 4% of patients underwent 
re‑challenge with vinflunine and 8% received different chemo-
therapy after vinflunine, primarily taxane‑based combination 
chemotherapy.
Toxicity. Grade 3 and 4 toxicities, according to NCI‑CTCAE 
version 4.0, were recorded in a total of 76% of patients treated 
with vinflunine. The specific adverse events are listed in 
Table III. The proportion of patients with ≥1 grade 3/4 toxicity 
was significantly higher in those with ECOG PS 2 than in 
those with ECOG PS 0‑1 (95 vs. 71%, respectively; P=0.026). 
The patients with ECOG PS 2 also exhibited a significantly 
higher frequency of fatigue compared with ECOG PS 0‑1 
patients (P=0.012). 
Response. The overall response rate to second‑line vinflunine 
chemotherapy was 23%; 1% of patients exhibited a complete 
response (CR) and 22% exhibited a partial response (PR). The 
disease control rate (DCR) was 55% (Fig. 1). For patients with 
ECOG PS 0‑1, 2% exhibited CR, 27% PR and 64% DCR. No 
Table II. Vinflunine treatment, response and survival parameters.
 All patients ECOG PS 0‑1 ECOG PS 2
Parameter (n=100) (n=80) (n=20)
Line of vinflunine therapy
  First 5 (5) 3 (4)   2 (10)
  Second 94 (94) 76 (95) 18 (90)
  Third 1 (1) 1 (1) 0 (0)
Cycles, n
  Median 3 4 2
  Range 1‑28 1‑18 1‑21
Initial dose, mg/m2
  320 33 (35) 31 (41)   2 (10)
  280 44 (46) 34 (45) 10 (53)
  250 18 (19) 11 (14)   7 (37)
Responsea
  CR 1 (1) 1 (2) 0 (0)
  PR 17 (22) 17 (27) 0 (0)
  SD 25 (32) 22 (35)   3 (20)
  PD 34 (44) 22 (35) 12 (80)
mPFS, months 
  Median 2.8 2.8 1.8
  Range 0.5‑34.3 0.7‑34.3 1.4‑14.7
mOS, months 
  Median 6.3 7.0 4.1
  Range 0.3‑39.7 0.3‑39.7 1.2‑16.3
All data, excluding cycles, mPFS and mOS, are presented as n (%). aIn total, 18 patients did not undergo radiological evaluation. ECOG 
PS, Eastern Cooperative Oncology Group performance status; CR, complete response; PR, partial response; SD, stable disease; PD, progres-
sive disease; mPFS, median progression‑free survival; mOS, median overall survival.
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responses were noted for patients with ECOG PS 2; instead, 
20% of the patients presented stable disease (SD) as best 
response. In the whole study population, patients presenting 
CR or PR had significantly longer mOS compared with those 
with SD or progressive disease (PD) (13.8 vs. 6.1 months, 
respectively; P=0.028). In the ECOG PS 0‑1 and 2 groups, 
there were no significant difference in mOS between patients 
with CR or PR and those with SD or PD (data not shown).
Survival data. The mPFS and mOS were 2.8 (range, 0.5‑34.3) 
and 6.3 (range, 0.3‑39.7) months, respectively (Table II; 
Fig. 2A and B). Patients with ECOG PS 2 had short mPFS and 
mOS (1.8 and 4.1 months, respectively). Among patients with 
ECOG PS 0‑1, OS was >12 months in 21% and >24 months 
in 5%. The corresponding proportions for patients with 
ECOG PS 2 were 10 and 0%, respectively. No significant 
difference in OS in association with the presence or absence 
of ≥1 grade 3/4 toxicity was noted in either of the cohorts 
(data not shown).
Prognostic factors. Performance status was strongly associ-
ated with OS. The mOS was significantly shorter for patients 
with ECOG PS 2 compared with those with ECOG PS 0‑1 
[4.1 (range 1.2‑16.3) vs. 7.0 (range 0.3‑39.7) months, P=0.001; 
Fig. 3A]. Furthermore, the mOS was significantly longer for 
patients without visceral metastases at onset of vinflunine treat-
ment (22%) compared with patients with such metastases at 
that time [10.6 (range 1.6‑39.7) vs. 6.0 (range 0.3‑28.1) months, 
P=0.008; Fig. 3B]. The mOS were 18.1 months for patients 
with ECOG PS 0‑1 and no visceral metastases (20%). Pres-
ence of liver metastasis or Hb <10 g/dl was not significantly 
correlated with OS. Also, none of the following parameters 
showed significant correlations with OS: Alkaline phospha-
tase, the initial dose of vinflunine, age of >65 years or presence 
of grade 3/4 toxicity.
The number of cycles of chemotherapy administered 
prior to the onset of vinflunine was significantly correlated 
with OS (P=0.016), in favor for patients who had previously 
received ≥6 cycles of platinum‑containing chemotherapy 
compared with those administered <6 cycles (6.9 vs. 
4.7 months). Such a correlation was also observed in the 
group with ECOG PS 0‑1 (P=0.029), but not in the group 
with ECOG PS 2 (P=0.480).
Table III. Safety according to grade 3/4 toxicitya.
 All patients ECOG PS 0‑1 ECOG PS 2
Toxicity (n=100) (n=80) (n=20) P‑value
Hematological 
  Anemia 33 (33) 23 (29) 10 (50) 0.071
  Neutropenia 23 (23) 19 (24) 4 (20) 0.722
  Febrile neutropenia 13 (13) 10 (13) 3 (15) 0.766
  Thrombocytopenia 3 (3) 3 (4) 0 (0) 0.379
Non‑hematological 
  Fatigue 36 (36) 24 (30) 12 (60) 0.012
  Constipation 22 (22) 20 (25) 2 (10) 0.148
  Abdominal pain 12 (12) 8 (10) 4 (20) 0.218
  Infusion site reaction 5 (5) 4 (5) 1 (5) 1.000
  Stomatitis 4 (4) 4 (5) 0 (0) 0.518
  Nausea 2 (2) 2 (3) 0 (0) 0.475
  Vomiting 2 (2) 2 (3) 0 (0) 0.475
  Myalgia 2 (2) 2 (3) 0 (0) 0.475
≥1 Toxicity  76 (76) 57 (71) 19 (95) 0.026
All data are presented as n (%). aGraded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (ver-
sion 4.0). P‑value showing the difference between ECOG PS 0‑1 and 2 was assessed by the Pearson's χ2 test. ECOG PS, Eastern Cooperative 
Oncology Group performance status.
Figure 1. Comparison of response to vinflunine treatment in patients with 
mUC subdivided into three groups. CR, complete response; PR, partial 
response; SD, stable disease; PD, progressive disease; ECOG PS, Eastern 
Cooperative Oncology Group performance status.
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Discussion
Platinum‑refractory mUC is a medical challenge due to the 
aggressiveness of the disease and the heterogeneity of the 
patient population. Certain patients with mUC present with 
slowly progressing limited disease and good performance 
status, whereas others may present with large‑volume disease 
that affects vital organs, impaired renal function, significant 
co‑morbidity and poor overall performance status. Further-
more, the inter‑individual sensitivity to chemotherapy differs, 
and represents an additional factor that is uncontrollable and 
influences the benefits of the treatment administered.
No standard second‑line chemotherapy for mUC was previ-
ously available, however, in 2009, the use of vinflunine was 
approved based on positive results of a randomized phase III 
trial demonstrating its beneficial effects on OS (12). Further-
more, the overall response rate, disease control rate and PFS 
for vinflunine all significantly favored treating patients with 
this drug as opposed to providing best supportive care only, 
thus strengthening the rationale for offering vinflunine to 
platinum‑refractory patients. The European Medical Agency 
has approved vinflunine as a second‑line treatment and the 
compound is recommended with the highest level of evidence 
in the European Association of Urology guidelines (14). In 
the current study, the first 100 patients treated with vinflunine 
at three high‑volume cancer centers affiliated with NUCOG 
were retrospectively analyzed. The overall aim was to evaluate 
treatment patterns, efficacy data and side effects of vinflunine 
in a real‑world clinical setting, and also to relate those aspects 
to previously demonstrated prognostic factors for mUC in 
patients treated with second‑line chemotherapy.
It was identified that the patients included in the present 
study were heterogeneous with regard to the line of vinflunine 
treatment and ECOG PS. In addition, these patients differed 
from those included in the phase III trial conducted by Bell-
munt et al (12), all of whom were treated with second‑line 
vinflunine therapy and had an ECOG PS of <2. More specifi-
cally, 20% of the patients in the current study presented with 
Figure 2. Survival data for patients with metastatic urothelial carcinoma treated with vinflunine as second‑line chemotherapy, illustrated by Kaplan‑Meier 
curves. (A) mPFS of 2.8 months (range, 0.5‑34.3 months) and (B) mOS of 6.3 months (range, 0.3‑39.7 months). mPFS, median progression‑free survival; mOS, 
median overall survival.
Figure 3. Kaplan‑Meier curves illustrating mOS data for patients with metastatic urothelial carcinoma treated with vinflunine as second‑line chemotherapy 
in relation to different prognostic factors. (A) OS as a function of ECOG PS 0‑1 vs. ECOG PS 2 (mOS: 7.0 vs. 4.1 months; P=0.001). (B) OS as a function 
of absence vs. presence of visceral metastases (mOS: 10.6 vs. 6.0 months; P=0.008). ECOG PS, Eastern Cooperative Oncology Group performance status; 
mOS, median overall survival.
  A   B
  A   B
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ECOG PS 2 at onset of treatment, and 5% of the patients 
were treated with first‑line and 1% with third‑line vinflunine 
therapy. ECOG PS is well known to predict the benefit of 
subsequent chemotherapy in mUC patients (19,24); therefore, 
two sub‑cohorts were identified for further comparison: 
Patients with ECOG PS 0‑1 and patients with ECOG PS 2.
The mPFS and mOS were marginally shorter in the present 
study (2.8 and 6.3 months) compared with the phase III 
trial (3.0 and 6.9 months) conducted by Bellmunt et al (12), 
possibly because survival data were calculated from the first 
day of vinflunine treatment in the current investigation but 
from the randomization date in the previous trial. Patients 
with ECOG PS 2 had significantly shorter mOS (4.1 months) 
compared with those with ECOG PS 0‑1 (7.0 months), and they 
also had higher rates of grades 3 and 4 toxicity. The present 
study is the first to evaluate ECOG PS 2 patients treated 
with vinflunine and the results demonstrate that, in general, 
vinflunine should be used with caution in such patients. This 
finding agrees with the conclusions that De Santis et al (28) 
reported after evaluating chemotherapy in a cisplatin‑unfit 
population, including ECOG PS 2 patients.
The patients in the current cohort underwent a median 
of 3 cycles of vinflunine, which is similar to treatment 
with this drug in the trial by Bellmunt et al (12). However, 
the inter‑individual variation in the number of vinflunine 
cycles was large (range, 1‑28 cycles) in the present study, 
which indicates significant differences in treatment benefit. 
Re‑exposure to vinflunine in a second course of treatment was 
performed in 4% of the patients that exhibited clinical benefit 
after the first series of vinflunine treatment; these patients 
were entered into surveillance but eventually progressed. 
Future studies should explore this re‑exposure approach 
in selected patients showing a significant clinical benefit 
after the first series of vinflunine treatment. A considerable 
proportion of the vinflunine‑treated patients in the phase III 
trial were identified as long‑term survivors: 27% with OS 
>12 months and 11% with OS >24 months (13). Similarly, 
in the current trial, 23% had an OS >12 months and 5% had 
an OS of >24 months. It is possible that such patients harbor 
tumors with an extraordinary vinflunine‑sensitive genotype, 
however, no biomarkers from patient tumor samples or other 
tissues have yet been identified as predictive of the efficacy 
of vinflunine treatment.
The patients without visceral metastases at the time 
of initiation of vinflunine had a significantly longer mOS 
compared with patients with such metastases at that time 
(10.6 vs. 6.0 months, P=0.008), supporting previous observa-
tions that this parameter is of high prognostic value (17,23). 
In the present study, mOS was significantly shorter for 
patients with ECOG PS 2 than for those with ECOG PS 0‑1 
(P=0.001). Furthermore, the presence of liver metastases and 
<10 g/dl Hb were not of prognostic value, possibly due to the 
heterogeneity in vinflunine treatment and performance status 
(ECOG PS 0‑2).
In summary, to the best of our knowledge, the present 
study represents the largest retrospective analysis conducted 
to date to focus on advanced mUC treated with vinflunine, and 
the results confirmed the activity of this drug in an unselected 
cohort of patients treated in routine clinical practice. The 
median PFS and OS values observed are similar to data 
obtained in a previous randomized phase III trial. The patients 
with ECOG PS 2 had a shorter mOS and a higher frequency of 
severe toxicity; hence, such individuals should be treated with 
caution. ECOG PS >1 and the presence of visceral metastases 
were confirmed as significantly adverse prognostic parameters 
that should be taken into consideration when prescribing 
vinflunine treatment. Notably, large inter‑individual differ-
ences were identified regarding OS and radiological response. 
The aforementioned observations call for the development of 
improved patient selection tools that should preferably include 
tumor biomarkers relevant for determining the sensitivity to 
vinflunine treatment.
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